Gene therapy company Latus Bio has closed a $97 million Series A financing to support its therapeutics pipeline.   The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund.   Korea Development Bank and Helen’s Pink Sky Foundation […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!